---
title: "Open Orphan PLC (AIM:ORPH) Change of name to hVIVO plc effective"
publisher: "Share Talk"
author: "sharetalk"
published: "2022-10-25T06:42:07+00:00"
modified: "2022-10-25T06:42:07+00:00"
date: 2022-10-25
canonical: "https://www.share-talk.com/open-orphan-plc-aimorph-change-of-name-to-hvivo-plc-effective/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["Andrew Catchpole", "antiviral", "breast cancer", "Cathal Friel", "CHIMagents", "clinical respiratory drug", "Codagenix", "COVID-19", "Dengue Fever", "Dr Andrew Catchpole", "Dr Chris Chiu", "Gregory Stoloff", "hVIVO", "HVO", "Imperial College London", "Imutex Ltd", "laboratory", "Malaria", "Open Orphan", "ORPH", "Oxford BioTherapeutics", "pharmaceutical", "quarantine clinic", "Rahim Fandi", "Share Talk", "The Lancet", "Vaccine", "virology", "West Nile Virus", "Zika"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Open Orphan PLC (AIM:ORPH) Change of name to hVIVO plc effective

**Published:** October 25, 2022
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** Andrew Catchpole, antiviral, breast cancer, Cathal Friel, CHIMagents, clinical respiratory drug, Codagenix, COVID-19, Dengue Fever, Dr Andrew Catchpole, Dr Chris Chiu, Gregory Stoloff, hVIVO, HVO, Imperial College London, Imutex Ltd, laboratory, Malaria, Open Orphan, ORPH, Oxford BioTherapeutics, pharmaceutical, quarantine clinic, Rahim Fandi, Share Talk, The Lancet, Vaccine, virology, West Nile Virus, Zika
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**Open Orphan plc (AIM: ORPH),** a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to its announcement on8 September 2022, the Company’s change of name to** hVIVO plc (AIM: HVO)** has now been completed and is expected to take effect on AIM and Euronext Growth from** 8.00 am tomorrow.**

The Company’s ticker will be **HVO** and the website address (including the investor relations content and the information required by AIM Rule 26 and Euronext Growth Rule 3.4) will be available at [www.hvivo.com](http://www.hvivo.com).

The Company’s ISIN (GB00B9275X97) and SEDOL (B9275X9) will remain the same.

Shareholders will be unaffected by the change of name and existing share certificates should be retained and will remain valid. Any new share certificates issued after the name change takes effect will bear the name hVIVO plc.

For further information please contact:

**Open Orphan plc**

**+44 (0) 20 7756 1300**

**Yamin Khan, Chief Executive Officer**

---

**Original URL:** https://www.share-talk.com/open-orphan-plc-aimorph-change-of-name-to-hvivo-plc-effective/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*